Paris, France and Camberley, UK – 3 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of two new polymerase chain reaction (PCR) assays, expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 variant detection portfolios. http://novacyt.com/wp-content/uploads/2021/06/Novacyt-Launch-of-two-new-PCR-COVID-19-assays-final.pdf
Visit PageCategory: Board
Launch of VersaLab™ Portable
Paris, France and Camberley, UK – 26 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ portfolio with the launch of VersaLab™ Portable to provide an additional level of support in near-patient testing environments. http://novacyt.com/wp-content/uploads/2021/05/Expansion-of-VersaLab-final-ENGLISH-.pdf
Visit PageInclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range
Paris, France and Camberley, UK – 17 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s SNPsig® SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England Framework for detecting Variants of Concern (VoC). Novacyt also announces the launch of two
Visit PageLaunch of mobile processing laboratories to detect COVID-19
Paris, France and Camberley, UK – 17 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ service with the launch of mobile processing laboratories (MPL) to provide rapid turnaround polymerase chain reaction (PCR) testing on-site. Testing will be performed using mid-nose nasal swabs,
Visit PageHoldings in Company
Paris, France and Camberley, UK – 13 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 12 January 2021 that, as at 11 January 2021 BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.95% (2,085,368 shares). http://novacyt.com/wp-content/uploads/2021/01/Novacyt-BlackRock-holdings-13.01.2021-ENGLISH.pdf
Visit PageDirector/PDMR Shareholding
Paris, France and Camberley, UK – 18 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 12 November 2020, Anouska Penny-Gibson, a person closely associated (PCA) to Steve Gibson, a PDMR of Novacyt, acquired 697 ordinary shares of €1/15 each in
Visit PageR&D Update
Continued expansion of COVID-19 product portfolio to address unmet market needs Paris, France and Camberley, UK – 16 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&D update. http://novacyt.com/wp-content/uploads/2020/11/Novacyt-RD-Update-16-11-20-ENGLISH.pdf
Visit PageDirector/PDMR Shareholding
Paris, France and Camberley, UK – 11 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 10 November 2020, Edwin Snape, a Non-Executive Director of the Company, purchased 1,080 ordinary shares of €1/15 each in the Company at a price of
Visit PageAcquisition de IT-IS International Ltd
Une acquisition en ligne avec la stratégie, qui garantit la propriété intellectuelle clé pour les instruments de PCR rapide du Groupe et étend ses capacités de base et son offre de produits Paris, France et Camberley, Royaume-Uni – 15 octobre 2020 –Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce l’acquisition de
Visit PageAcquisition of IT-IS International Ltd
Deal in line with strategy, secures key IP for the Company’s rapid-PCR instruments, expands its core capabilities and product offering Paris, France and Camberley, UK – 15 October 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the acquisition of the entire share capital of IT-IS International Ltd (IT-IS),
Visit Page